Replimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of “Reduce” from Brokerages

Shares of Replimune Group, Inc. (NASDAQ:REPL) have received a consensus rating of “Reduce” from the ten research firms that are presently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell recommendation and seven have given a hold recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $4.8750.

REPL has been the topic of several research reports. Cantor Fitzgerald downgraded shares of Replimune Group from an “overweight” rating to a “hold” rating in a research note on Monday, April 13th. BMO Capital Markets downgraded shares of Replimune Group from a “market perform” rating to an “underperform” rating in a research note on Monday, April 13th. Weiss Ratings downgraded shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, June 3rd. Jefferies Financial Group reissued a “hold” rating and set a $2.00 price target (down from $13.00) on shares of Replimune Group in a research note on Monday, April 13th. Finally, Leerink Partners reissued a “market perform” rating and set a $2.00 price target (down from $11.00) on shares of Replimune Group in a research note on Monday, April 13th.

Insider Activity at Replimune Group

In related news, insider Christopher Sarchi sold 12,000 shares of Replimune Group stock in a transaction on Monday, June 1st. The shares were sold at an average price of $9.24, for a total value of $110,880.00. Following the transaction, the insider directly owned 180,962 shares of the company’s stock, valued at $1,672,088.88. The trade was a 6.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. International Assets Investment Management LLC purchased a new position in shares of Replimune Group in the fourth quarter worth $29,000. Russell Investments Group Ltd. increased its stake in shares of Replimune Group by 3,638.9% in the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock worth $33,000 after buying an additional 7,569 shares during the period. CWM LLC increased its stake in shares of Replimune Group by 248.6% in the fourth quarter. CWM LLC now owns 4,047 shares of the company’s stock worth $39,000 after buying an additional 2,886 shares during the period. Essential Partners LLC increased its stake in shares of Replimune Group by 562,400.0% in the first quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock worth $43,000 after buying an additional 5,624 shares during the period. Finally, BNP Paribas Financial Markets increased its stake in shares of Replimune Group by 99.8% in the third quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock worth $58,000 after buying an additional 6,873 shares during the period. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Trading Down 2.0%

REPL stock opened at $8.78 on Wednesday. The company has a market capitalization of $724.99 million, a PE ratio of -2.55 and a beta of 0.88. Replimune Group has a one year low of $1.50 and a one year high of $13.24. The company’s 50 day moving average price is $5.27 and its two-hundred day moving average price is $7.25. The company has a debt-to-equity ratio of 0.33, a quick ratio of 5.60 and a current ratio of 5.60.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.